JP3946239B1 - Accelerating pulse wave aging index raising agent - Google Patents

Accelerating pulse wave aging index raising agent Download PDF

Info

Publication number
JP3946239B1
JP3946239B1 JP2006183236A JP2006183236A JP3946239B1 JP 3946239 B1 JP3946239 B1 JP 3946239B1 JP 2006183236 A JP2006183236 A JP 2006183236A JP 2006183236 A JP2006183236 A JP 2006183236A JP 3946239 B1 JP3946239 B1 JP 3946239B1
Authority
JP
Japan
Prior art keywords
pulse wave
aging index
acceleration pulse
wave aging
intake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2006183236A
Other languages
Japanese (ja)
Other versions
JP2008013443A (en
Inventor
忠士 江藤
Original Assignee
株式会社日本バリアフリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社日本バリアフリー filed Critical 株式会社日本バリアフリー
Priority to JP2006183236A priority Critical patent/JP3946239B1/en
Priority claimed from KR1020070066257A external-priority patent/KR101301037B1/en
Application granted granted Critical
Publication of JP3946239B1 publication Critical patent/JP3946239B1/en
Publication of JP2008013443A publication Critical patent/JP2008013443A/en
Active legal-status Critical Current

Links

Images

Abstract

【課題】魚類の卵巣膜から抽出された成分の新たな用途を提供する。
【解決手段】魚類の卵巣膜から抽出された成分を含む末梢血流改善剤であり、末梢血液循環の低下による諸症状を緩和、改善することができる。前記卵巣膜から抽出された成分は、該卵巣膜をタンパク分解酵素で処理することにより抽出された成分である。前記卵巣膜は、鮭の卵巣膜である。
【選択図】 図1
The present invention provides a new use of components extracted from ovarian membranes of fish.
A peripheral blood flow-improving agent containing a component extracted from the ovarian membrane of fish, which can alleviate and improve various symptoms caused by a decrease in peripheral blood circulation. The component extracted from the ovarian membrane is a component extracted by treating the ovarian membrane with a proteolytic enzyme. The ovarian membrane is a spider ovarian membrane.
[Selection] Figure 1

Description

本発明は、加速度脈波加齢指数上昇剤に関するものである。 The present invention relates to an acceleration pulse wave aging index raising agent .
従来、魚類の卵巣膜(魚卵外皮)を予めオゾン水で処理した後、その構成タンパク質である筋原線維タンパク質を酵素分解してアミノ酸及びペプチドを抽出する方法が知られている(例えば特許文献1参照)。   Conventionally, a method of extracting amino acids and peptides by treating the ovarian membrane (fish egg rind) of fish with ozone water in advance and then enzymatically degrading myofibrillar protein, which is a constituent protein thereof, is known (for example, patent document). 1).
前記アミノ酸及びペプチドは、生理活性物質として、あるいは食品強化剤として用いることができるとされており、さらに詳しくは、ACE阻害活性を備え、血圧上昇抑制剤(降圧剤)として作用するとされている。   The amino acids and peptides can be used as physiologically active substances or as food fortifiers. More specifically, the amino acids and peptides have ACE inhibitory activity and act as blood pressure increase inhibitors (hypertensive agents).
しかしながら、魚類の卵巣膜から抽出された成分には、さらに多くの用途の開発が望まれる。
特開2004−73186号公報
However, it is desired to develop more uses for the components extracted from the ovarian membrane of fish.
JP 2004-73186 A
本発明は、かかる事情に鑑み、魚類の卵巣膜から抽出された成分の新たな用途を提供することを目的とする。   In view of such circumstances, an object of the present invention is to provide a new use of a component extracted from the ovarian membrane of fish.
かかる目的を達成するために、本発明の加速度脈波加齢指数上昇剤は、鮭の卵巣膜をタンパク分解酵素で処理することにより抽出された成分を含むことを特徴とする。 In order to achieve this object, the accelerated pulse wave aging index increasing agent of the present invention is characterized by containing a component extracted by treating the ovarian membrane of sputum with a proteolytic enzyme .
生体においては、成年期を過ぎると加齢に伴って、肌荒れ、肩凝り、関節痛、むくみ、冷え性、貧血等の末梢血液循環の低下による諸症状が現れてくる。また、末梢血液循環の低下は、前記加齢だけではなく、低血圧、心臓のポンプ機能の低下、筋肉不足等が原因とされている。前記末梢血液循環の低下は、加速度脈波加齢指数の低下として把握される。   In the living body, after the adulthood, with aging, various symptoms appear due to a decrease in peripheral blood circulation such as rough skin, stiff shoulders, joint pain, swelling, coldness and anemia. The decrease in peripheral blood circulation is caused not only by the above-mentioned aging but also by low blood pressure, a decrease in heart pump function, muscle shortage, and the like. The decrease in the peripheral blood circulation is grasped as a decrease in the acceleration pulse wave aging index.
加速度脈波加齢指数とは、末梢血管の柔軟性を示す指標である。例えば指尖は、心臓から拍出された血液が動脈を経て静脈に至る折り返し部分である。指尖の末梢血管に流れる血液の量(容積)の変化を測定することにより、末梢血管の膨張・収縮状況を波形として得ることができ、この波形を「指尖脈波」という。指尖脈波を2階微分することにより、心臓の収縮期の波形を示す加速度脈波が得られる。例えば図6示の加速度脈波には4つの波があり、a波を収縮初期陽性波、b波を収縮初期陰性波、c波を収縮中期再上昇波、d波を収縮後期再下降波という。a波とb波とは血液の駆出によって生ずる駆動圧波に依存し、c波とd波とは駆動圧波が末梢に伝搬し反射して戻ってきた反射圧波に依存している。加速度脈波の波形から“{(−b+c+d)/a}×100”の式により加速度脈波加齢指数が得られる。なお、前式における“a”,“b”,“c”,“d”はa波、b波、c波、d波の高さである。加速度脈波加齢指数は一般に−120〜120の値をとり、値が大きいほど末梢血管が柔軟で、末梢血液循環が良好であることを示している。   The acceleration pulse wave aging index is an index indicating the flexibility of peripheral blood vessels. For example, the fingertip is a folded portion where blood pumped from the heart passes through an artery and reaches a vein. By measuring the change in the volume (volume) of blood flowing in the peripheral blood vessels of the fingertips, the expansion / contraction state of the peripheral blood vessels can be obtained as a waveform, and this waveform is called “fingertip pulse wave”. An acceleration pulse wave showing a waveform of the systole of the heart is obtained by second-order differentiation of the fingertip pulse wave. For example, the acceleration pulse wave shown in FIG. 6 has four waves, the a wave being the initial contraction positive wave, the b wave being the initial contraction negative wave, the c wave being the middle systolic re-rising wave, and the d wave being the late systolic re-falling wave. . The a wave and the b wave depend on the driving pressure wave generated by the ejection of blood, and the c wave and the d wave depend on the reflected pressure wave that the driving pressure wave propagates to the periphery and is reflected back. The acceleration pulse wave aging index is obtained from the waveform of the acceleration pulse wave by the formula “{(−b + c + d) / a} × 100”. Note that “a”, “b”, “c”, and “d” in the previous equation are the heights of the a wave, b wave, c wave, and d wave. The acceleration pulse wave aging index generally takes a value of −120 to 120, and the higher the value, the more flexible the peripheral blood vessels and the better the peripheral blood circulation.
本願発明者等は、本発明の加速度脈波加齢指数上昇剤を被験者に摂取させ、加速度脈波加齢指数を用いて末梢血液循環の状態を検査したところ、末梢血液循環の低下による諸症状を緩和、改善することができることを知見した。 The inventors of the present application ingested the accelerated pulse wave aging index increasing agent of the present invention, and examined the peripheral blood circulation state using the accelerated pulse wave aging index, various symptoms due to a decrease in peripheral blood circulation It was found that this can be relaxed and improved.
次に、添付の図面を参照しながら本発明の実施の形態についてさらに詳しく説明する。図1は本実施形態の加速度脈波加齢指数上昇剤を8週間摂取した後の体調と摂取中止から2週間後の体調との比較を示すグラフ、図2は本実施形態の加速度脈波加齢指数上昇剤を摂取した場合とプラセボ(偽薬)を摂取した場合との加速度脈波加齢指数の経時的変化を示すグラフ、図3は本実施形態の加速度脈波加齢指数上昇剤を摂取した場合とプラセボを摂取した場合との加速度脈波加齢指数の変化量を示すグラフ、図4は本実施形態の加速度脈波加齢指数上昇剤を摂取した場合とプラセボを摂取した場合とのIGF−1値の経時的変化を示すグラフ、図5は本実施形態の加速度脈波加齢指数上昇剤を摂取した場合とプラセボを摂取した場合とのIGF−1値の変化量を示すグラフである。 Next, embodiments of the present invention will be described in more detail with reference to the accompanying drawings. FIG. 1 is a graph showing a comparison between the physical condition after ingesting the acceleration pulse wave aging index increasing agent of this embodiment for 8 weeks and the physical condition after 2 weeks from the discontinuation of intake, and FIG. 2 is an acceleration pulse wave addition of this embodiment. FIG. 3 is a graph showing the change over time of the acceleration pulse wave aging index when taking an age index increasing agent and when taking a placebo (placebo), FIG. 3 is taking the acceleration pulse wave aging index increasing agent of this embodiment FIG. 4 is a graph showing the amount of change in the acceleration pulse wave aging index when taking a placebo and when taking a placebo, and FIG. 4 shows the case where the acceleration pulse wave aging index increasing agent of this embodiment is taken and the placebo is taken FIG. 5 is a graph showing the amount of change in IGF-1 value when the accelerated pulse wave aging index raising agent of this embodiment is ingested and when the placebo is ingested. is there.
本実施形態の加速度脈波加齢指数上昇剤は、鮭の卵巣膜から抽出された成分(以下、卵巣膜抽出成分と略記する)を含む。前記卵巣膜抽出成分は、鮭の卵巣膜を酵素処理してタンパク質を抽出した溶液を濾過し、得られた濾液を乾燥させる方法等により得ることができる。 The acceleration pulse wave aging index increasing agent of the present embodiment contains a component extracted from the ovarian membrane of rabbit (hereinafter abbreviated as an ovarian membrane extraction component). The ovarian membrane extract component can be obtained by, for example, a method of filtering a solution obtained by enzymatic treatment of salmon ovarian membrane and drying the obtained filtrate.
前記方法では、具体的には、まず、鮭の卵巣膜を原料とし、該卵巣膜に対して水を卵巣膜:水=1:1〜1:3の重量比で加えて撹拌、混合し、さらにタンパク分解酵素を卵巣膜の全量に対して1〜3重量%の範囲で添加し、45〜55℃の温度で30分間〜5時間、好ましくは2時間加熱する。このようにすると、前記卵巣膜の成分のうち、前記タンパク分解酵素で分解された成分が水中に溶出し、該成分の水溶液が得られる。   Specifically, in the method, first, the ovarian membrane of the pupa is used as a raw material, and water is added to the ovarian membrane in a weight ratio of ovarian membrane: water = 1: 1 to 1: 3, and the mixture is stirred and mixed. Furthermore, a proteolytic enzyme is added in the range of 1 to 3% by weight with respect to the total amount of the ovarian membrane, and heated at a temperature of 45 to 55 ° C. for 30 minutes to 5 hours, preferably 2 hours. If it does in this way, the component decomposed | disassembled with the said proteolytic enzyme will elute in water among the components of the said ovary membrane, and the aqueous solution of this component will be obtained.
次に、前記水溶液に含まれている前記タンパク分解酵素を失活する。前記失活は、例えば、前記水溶液を90℃の温度で5分間加熱することにより行うことができる。   Next, the proteolytic enzyme contained in the aqueous solution is inactivated. The deactivation can be performed, for example, by heating the aqueous solution at a temperature of 90 ° C. for 5 minutes.
次に、前記水溶液を30メッシュ程度の金網で簡易濾過し、未分解の卵巣膜等の粗大物を除去する。そして、得られた濾液に活性炭を添加して、該濾液の脱臭、脱色、脱脂を行う。前記濾液の脱臭、脱色、脱脂は、前記原料としての卵巣膜の全量に対して2〜4重量%の範囲の活性炭を該濾液に添加し、例えば60℃の温度で30分間加熱することにより行うことができる。   Next, the aqueous solution is simply filtered through a wire mesh of about 30 mesh to remove coarse materials such as undecomposed ovarian membranes. Then, activated carbon is added to the obtained filtrate to deodorize, decolorize, and degrease the filtrate. The deodorization, decolorization, and degreasing of the filtrate is performed by adding activated carbon in the range of 2 to 4% by weight to the total amount of the ovarian membrane as the raw material and heating the filtrate at a temperature of 60 ° C. for 30 minutes, for example. be able to.
前記活性炭による脱臭、脱色、脱脂処理後、前記濾液を例えばフィルタープレスにより濾過し、得られた濾液を、減圧下、例えば60℃の温度で濃縮した後、例えば80℃の温度に10分間維持して滅菌する。そして、滅菌後の前記濾液をスプレードライにて乾燥させることにより、前記卵巣膜抽出成分を得ることができる。前記卵巣膜抽出成分は、アミノ酸、ペプチド、ビタミン、ミネラル、糖類、酵素、核酸及びその代謝物、各種成長因子、サイトカイン等を含んでいる。   After the deodorization, decolorization, and degreasing treatment with the activated carbon, the filtrate is filtered by, for example, a filter press, and the obtained filtrate is concentrated at a temperature of 60 ° C. under reduced pressure, for example, and then maintained at a temperature of 80 ° C. for 10 minutes, for example. And sterilize. Then, the ovarian membrane extract component can be obtained by drying the sterilized filtrate by spray drying. The ovarian membrane extract component contains amino acids, peptides, vitamins, minerals, sugars, enzymes, nucleic acids and their metabolites, various growth factors, cytokines, and the like.
本実施形態の加速度脈波加齢指数上昇剤は、前記卵巣膜抽出成分を、例えば錠剤等の形に製剤したものであり、例えば健康食品等の食品として摂取することにより、末梢血液循環の低下による諸症状を緩和、改善することができる。 The acceleration pulse wave aging index increasing agent of the present embodiment is prepared by formulating the ovarian membrane extract component, for example, in the form of a tablet or the like. For example, by taking it as a food such as a health food, the peripheral blood circulation is reduced. Can alleviate and improve symptoms.
次に、本発明の実施例と比較例とを示す。   Next, examples of the present invention and comparative examples will be described.
本実施例では、まず、鮭の卵巣膜抽出成分を錠剤の形に製剤して、加速度脈波加齢指数上昇剤を製造した。前記錠剤は、前記卵巣膜抽出物245mg、賦形剤(ラブリワックス(登録商標))5mgからなり、8mmの直径を備えている。 In this example, first, an ovarian membrane extract component of sputum was formulated in the form of a tablet to produce an acceleration pulse wave aging index raising agent . The tablet consists of 245 mg of the ovarian membrane extract and 5 mg of excipient (Loveli wax (registered trademark)) and has a diameter of 8 mm.
次に、38〜42歳の健康な女性モニター10名に、前記錠剤を健康食品として1日当たり4錠、8週間に亘って摂取させた。なお、各モニターは、1ヶ月前からサプリメント、薬品(漢方薬を含む)の摂取を行っていない。   Next, 10 healthy female monitors aged 38 to 42 years old took 4 tablets per day for 8 weeks as a health food. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.
そして、各モニターの自己申告による体調について、摂取開始から8週間目と、摂取中止から2週間後との状態を比較した。結果を図1に示す。   And about the physical condition by the self-report of each monitor, the state of the 8th week after an intake start and the 2 weeks after an intake stop was compared. The results are shown in FIG.
また、摂取開始前、摂取開始から8週間目に、右手人差し指の先端(指尖)の末梢血液循環の状態を検査し、加速度脈波加齢指数を得た。   Further, before the start of ingestion and 8 weeks after the start of ingestion, the peripheral blood circulation at the tip (fingertip) of the right index finger was examined to obtain an acceleration pulse wave aging index.
末梢血液循環の状態は、次のように検査された。株式会社フューチャー・ウェイブ製の加速度脈波計(BCチェッカー(登録商標))を用いて、右手人差し指の指尖部をセンター部位に接触させる。加速度脈波計は、指尖部に近赤外光(波長950nm)を照射し、皮下組織内で散乱され血液により吸収された後に体外に放出された光を捉えて指尖脈波の波形を出力し、指尖脈波の波形を2階微分することによって得られた加速度脈波の波形を出力する。そして、加速度脈波の波形から加速度脈波加齢指数が得られる。   Peripheral blood circulation status was examined as follows. Using an acceleration sphygmograph (BC Checker (registered trademark)) manufactured by Future Wave Inc., the fingertip of the right index finger is brought into contact with the center part. The acceleration pulse wave meter irradiates the fingertip with near-infrared light (wavelength 950 nm), captures the light scattered outside the subcutaneous tissue and absorbed by the blood and then released outside the body, and generates the waveform of the fingertip pulse wave The waveform of the acceleration pulse wave obtained by second-order differentiation of the waveform of the fingertip pulse wave is output. The acceleration pulse wave aging index is obtained from the waveform of the acceleration pulse wave.
前記モニター10人の加速度脈波加齢指数の平均値を図2に、摂取開始から8週間目までの加速度脈波加齢指数の平均値の変化量を図3に、それぞれ示す。なお、図2中、摂取開始前を「0週」、摂取開始から8週間目を「8週」と記載し、図3中、摂取開始から8週間目までを「0−8週」と記載する。   The average value of the acceleration pulse wave aging index of the 10 monitors is shown in FIG. 2, and the amount of change in the average value of the acceleration pulse wave aging index from the start of intake to the 8th week is shown in FIG. In FIG. 2, “0 week” is indicated before the start of ingestion, “8 week” is indicated after the 8th week from the start of ingestion, and “0-8 weeks” is indicated from the start of intake to the 8th week in FIG. 3. To do.
さらに、摂取開始前、摂取開始から4週間目、摂取開始から8週間目に、血液検査を行い、インシュリン成長因子−1(IGF−1:Insulin−like Growth Factor−1)値を測定した。なお、IGF−1とは、インシュリンに非常に似た構造を持つポリペプチドである。IGF−1値は加齢に伴って低下し、一旦下降したIGF−1値が再度上昇することはないといわれている。   Further, before the start of ingestion, 4 weeks after the start of ingestion and 8 weeks after the start of ingestion, blood tests were performed to measure insulin growth factor-1 (IGF-1: Insulin-like Growth Factor-1) values. IGF-1 is a polypeptide having a structure very similar to insulin. It is said that the IGF-1 value decreases with aging, and the once lowered IGF-1 value does not increase again.
前記モニター10人のIGF−1値の平均値を図4に、摂取開始から4週間目まで、摂取開始から8週間目までのIGF−1値の平均値の変化量を図5に、それぞれ示す。
〔比較例〕
本比較例では、まず、前記実施例の加速度脈波加齢指数上昇剤に代えて、コーンスターチ125mg、乳糖125mgからなるプラセボ(偽薬)を、直径8mmの錠剤の形に製剤した。
The average value of IGF-1 values of the 10 monitors is shown in FIG. 4, and the change amount of the average value of IGF-1 values from the start of intake to the 4th week and from the start of intake to the 8th week is shown in FIG. .
[Comparative Example]
In this comparative example, first, a placebo (placebo) consisting of 125 mg of corn starch and 125 mg of lactose was formulated in the form of a tablet having a diameter of 8 mm instead of the acceleration pulse wave aging index raising agent of the above-mentioned example.
次に、前記実施例とは異なる38〜42歳の健康な女性モニター10名に、前記偽薬のカプセル剤を1日当たり4錠、8週間に亘って投与した。なお、各モニターは、1ヶ月前からサプリメント、薬品(漢方薬を含む)の摂取を行っていない。   Next, the placebo capsules were administered 4 times a day for 8 weeks to 10 healthy female monitors aged 38 to 42 years different from the Examples. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.
そして、前記実施例と全く同一にして、加速度脈波加齢指数とIGF−1値とを測定した。前記モニター10人の加速度脈波加齢指数の平均値を図2に、摂取開始から8週間目の加速度脈波加齢指数の平均値の変化量を図3に、前記モニター10人のIGF−1値の平均値を図4に、摂取開始から4週間目、摂取開始から8週間目のIGF−1値の平均値の変化量を図5に、それぞれ示す。   Then, the acceleration pulse wave aging index and the IGF-1 value were measured in exactly the same manner as in the above example. FIG. 2 shows the average value of the acceleration pulse wave aging index of the 10 monitors, FIG. 3 shows the amount of change in the average value of the acceleration pulse wave aging index 8 weeks after the start of intake, and FIG. FIG. 4 shows the average value of 1 values, and FIG. 5 shows the amount of change in the average value of IGF-1 values after 4 weeks from the start of intake and 8 weeks after the start of intake.
図1から、本実施形態の加速度脈波加齢指数上昇剤(実施例)によれば、本実施形態の加速度脈波加齢指数上昇剤を摂取中止から2週間後の体調よりも摂取開始から8週間目の体調の方が優れていることが明らかである。 From Figure 1, according to the acceleration pulse wave aging index increasing agent of the present embodiment (Example), the acceleration pulse wave aging index increasing agent of the present embodiment from the start of ingestion than physical condition after 2 weeks intake discontinued It is clear that the physical condition at 8 weeks is superior.
従って、本実施形態の加速度脈波加齢指数上昇剤を摂取したことによって、末梢血液循環の低下による諸症状が緩和、改善されたと考えられる。また、本実施形態の加速度脈波加齢指数上昇剤は、継続して摂取するのが効果的であると考えられる。 Therefore, it is considered that various symptoms due to the decrease in peripheral blood circulation were alleviated and improved by taking the acceleration pulse wave aging index increasing agent of this embodiment. Moreover, it is thought that it is effective to ingest the acceleration pulse wave aging index raising agent of this embodiment continuously.
また、図2から、本実施形態の加速度脈波加齢指数上昇剤によれば、摂取開始から8週間目には摂取開始前に比較して加速度脈波加齢指数が上昇していることが明らかである。これに対して、プラセボ(比較例)によれば、摂取開始から8週間目には摂取開始前に比較して低下していることが明らかである。 In addition, from FIG. 2, according to the acceleration pulse wave aging index increasing agent of the present embodiment, the acceleration pulse wave aging index is increased in the 8th week from the start of intake compared to before the start of intake. it is obvious. On the other hand, according to the placebo (comparative example), it is clear that in the 8th week from the start of intake, it is lower than that before the start of intake.
また、図3から、本実施形態の加速度脈波加齢指数上昇剤によれば、加速度脈波加齢指数が大きく上昇することが明らかである。 Moreover, it is clear from FIG. 3 that according to the acceleration pulse wave aging index increasing agent of the present embodiment, the acceleration pulse wave aging index increases greatly.
従って、本実施形態の加速度脈波加齢指数上昇剤を摂取したことによって、末梢血管の柔軟性が改善されたと考えられる。 Therefore, it is considered that the flexibility of peripheral blood vessels has been improved by taking the acceleration pulse wave aging index increasing agent of the present embodiment.
さらに、図4から、本実施形態の加速度脈波加齢指数上昇剤によれば、摂取開始から4週間目には摂取開始前に比較してIGF−1値が増加しており、摂取開始から8週間目には摂取開始から4週間目よりもさらに増加しており、単調に増加していることが明らかである。これに対して、プラセボによれば、摂取開始から8週間目には摂取開始前に比較してIGF−1値が増加しているものの、摂取開始から4週間目には摂取開始前に比較して一旦IGF−1値が減少しており、単調な増加ではないことが明らかである。 Furthermore, from FIG. 4, according to the acceleration pulse wave aging index increasing agent of this embodiment, the IGF-1 value increased compared to before the start of intake at 4 weeks from the start of intake, and from the start of intake. At 8 weeks, it is further increased from 4 weeks after the start of ingestion, and it is clear that it is increasing monotonously. On the other hand, according to the placebo, although the IGF-1 value increased in the 8th week from the start of the intake compared to before the start of the intake, it was compared in the 4th week after the start of the intake before the start of the intake. It is clear that the IGF-1 value has decreased once, not a monotonous increase.
また、図5から、本実施形態の加速度脈波加齢指数上昇剤によれば、IGF−1値の増加量がプラセボよりも大きいことが明らかである。 Moreover, from FIG. 5, according to the acceleration pulse wave aging index raising agent of this embodiment, it is clear that the increase amount of IGF-1 value is larger than a placebo.
従って、本実施形態の加速度脈波加齢指数上昇剤を摂取したことによって、IGF−1値が上昇したと考えられる。また、前述の末梢血液循環の低下による諸症状の緩和、改善は、IGF−1値の上昇も一因であると考えられる。 Therefore, it is considered that the IGF-1 value increased by taking the acceleration pulse wave aging index increasing agent of the present embodiment. In addition, the above-described alleviation and improvement of various symptoms due to the decrease in peripheral blood circulation is considered to be caused by an increase in IGF-1 level.
本発明に係る加速度脈波加齢指数上昇剤を8週間摂取した後の体調と摂取中止から2週間後の体調との比較を示すグラフ。The graph which shows the comparison with the physical condition after ingesting the acceleration pulse wave aging index raising agent which concerns on this invention for 8 weeks, and the physical condition after 2 weeks from ingestion. 本発明に係る加速度脈波加齢指数上昇剤を摂取した場合とプラセボ(偽薬)を摂取した場合との加速度脈波加齢指数の経時的変化を示すグラフ。The graph which shows the time-dependent change of the acceleration pulse wave aging index | exponent when the case where the acceleration pulse wave aging index raising agent which concerns on this invention is ingested, and the case where a placebo (placebo) is ingested. 本発明に係る加速度脈波加齢指数上昇剤を摂取した場合とプラセボを摂取した場合との加速度脈波加齢指数の変化量を示すグラフ。The graph which shows the variation | change_quantity of the acceleration pulse wave aging index of the case where the acceleration pulse wave aging index raising agent which concerns on this invention is ingested, and the case where a placebo is ingested. 本発明に係る加速度脈波加齢指数上昇剤を摂取した場合とプラセボを摂取した場合とのIGF−1値の経時的変化を示すグラフ。The graph which shows the time-dependent change of the IGF-1 value at the time of ingesting the case where the acceleration pulse wave aging index raising agent which concerns on this invention is ingested, and the placebo. 本発明に係る加速度脈波加齢指数上昇剤を摂取した場合とプラセボを摂取した場合とのIGF−1値の変化量を示すグラフ。The graph which shows the variation | change_quantity of the IGF-1 value when the case where the acceleration pulse wave aging index raising agent which concerns on this invention is ingested, and the placebo is ingested. 加速度脈波の一例を示すグラフ。The graph which shows an example of an acceleration pulse wave.
符号の説明Explanation of symbols
符号なし。   No sign.

Claims (1)

  1. 鮭の卵巣膜をタンパク分解酵素で処理することにより抽出された成分を含むことを特徴とする加速度脈波加齢指数上昇剤。 Accelerating pulse wave aging index increasing agent characterized by containing a component extracted by treating ovarian ovarian membrane with proteolytic enzyme .
JP2006183236A 2006-07-03 2006-07-03 Accelerating pulse wave aging index raising agent Active JP3946239B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006183236A JP3946239B1 (en) 2006-07-03 2006-07-03 Accelerating pulse wave aging index raising agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006183236A JP3946239B1 (en) 2006-07-03 2006-07-03 Accelerating pulse wave aging index raising agent
KR1020070066257A KR101301037B1 (en) 2006-07-03 2007-07-02 Antiaging agent

Publications (2)

Publication Number Publication Date
JP3946239B1 true JP3946239B1 (en) 2007-07-18
JP2008013443A JP2008013443A (en) 2008-01-24

Family

ID=38344679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006183236A Active JP3946239B1 (en) 2006-07-03 2006-07-03 Accelerating pulse wave aging index raising agent

Country Status (1)

Country Link
JP (1) JP3946239B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938866A2 (en) * 2006-12-22 2008-07-02 Nippon Barrier Free Co. Ltd. Cosmetic product comprising a component extracted from a Salmonidae fish ovarian
JP2012255036A (en) * 2012-10-02 2012-12-27 Nippon Barrier Free:Kk Anti-aging agent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938866A2 (en) * 2006-12-22 2008-07-02 Nippon Barrier Free Co. Ltd. Cosmetic product comprising a component extracted from a Salmonidae fish ovarian
EP1938866A3 (en) * 2006-12-22 2009-04-08 Nippon Barrier Free Co. Ltd. Cosmetic product comprising a component extracted from a Salmonidae fish ovarian
JP2012255036A (en) * 2012-10-02 2012-12-27 Nippon Barrier Free:Kk Anti-aging agent

Also Published As

Publication number Publication date
JP2008013443A (en) 2008-01-24

Similar Documents

Publication Publication Date Title
Harris et al. Effect of insulin hypoglycemia and glucose on various amino acids in blood of mental patients
TWI516280B (en) Use of chenopodium formosanum extract for manufacture of composition for enhancing secretion of collagen and preventing cutaneous aging
JP3946238B1 (en) IGF-1 level increasing agent
JP2002125662A (en) Non-deactivated enzyme-reinforced composition
JP2001031586A (en) Composition for prophylaxis or therapy of both arteriosclerosis and disease caused thereby
JP3946239B1 (en) Accelerating pulse wave aging index raising agent
JP3899116B1 (en) Skin roughening agent
AU2012354703B2 (en) Hydroxymethylfurfural derivative
JP5317501B2 (en) Fatigue reducing agent
CN106434806A (en) Cordyceps militaris polypeptide as well as preparation method and applications thereof
JP2014240366A (en) Therapeutic agent of arteriosclerosis with low-molecular fraction of grifola gargal extract
JP2008037770A (en) Anti-aging agent
EP1433500B1 (en) Blood fluidity-improving health foods
CN104857034A (en) Functional food for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof
JP2001048794A (en) Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm
JP4163801B2 (en) Alcohol metabolism promoting agent
JP6565085B2 (en) Hypoglycemic symptoms relieving agent
RU2384341C1 (en) Pharmaceutical composition for psoriasis treatment
JP2005029488A (en) Hypotensive agent and gly-pro
JP2018070602A (en) Anti-fatigue food composition and anti-fatigue agent
JP2001026753A (en) Composition for prophylaxis or treatment of hypertension
JP2019210269A (en) Composition for treating diabetic disease
JP2019172642A (en) Sleep quality improver
Okwuonu et al. Case Report the Potential Anti Hypertensive effects of the African Oil-bean Seed-Pentaclethra Macrophylla Bentham
JP6245924B2 (en) Glucose level rise inhibitor, Glucose level rise inhibitory food, and Glucose level rise inhibitory cosmetic

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070320

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070410

R150 Certificate of patent or registration of utility model

Ref document number: 3946239

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100420

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110420

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120420

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130420

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140420

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250